Who May Qualify for Valeda Light Therapy for Dry AMD in the United States
Valeda light therapy is intended for selected adults in the United States with dry age-related macular degeneration, based on clinical findings rather than a one-size-fits-all approach. Eye specialists typically review the type and stage of AMD, retinal imaging results, and other eye health factors before deciding whether treatment may be appropriate. Understanding these criteria helps clarify where the therapy fits in dry AMD care for patients in the U.S.
Choosing whether Valeda light therapy is suitable for a person with dry age-related macular degeneration usually involves more than a simple diagnosis. Retina specialists generally look at the pattern of disease in the macula, how vision is functioning, and whether the eye appears stable enough for a light-based treatment plan. In the United States, candidacy is individualized, so two people with the same general diagnosis may receive different recommendations based on their eye exam, imaging, and overall ocular history.
This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.
Eligibility criteria for dry AMD treatment
A patient is typically considered only after dry AMD has been clearly identified rather than wet AMD. That distinction matters because wet AMD involves abnormal blood vessel growth and leakage, which usually calls for a different treatment approach. Many specialists also look at the stage of dry AMD, since light therapy is commonly discussed in patients who still have retinal tissue that may benefit from treatment rather than eyes with severe end-stage damage. Diagnosis is usually confirmed through a dilated eye exam, retinal imaging, and vision testing rather than symptoms alone.
In practical terms, eligibility criteria for dry AMD treatment may include having non-exudative AMD, measurable visual function, and the ability to complete a series of in-office sessions. A clinician may also consider whether one eye or both eyes are affected, whether the macula can be visualized clearly, and whether the person can maintain fixation during treatment. The goal is to match the therapy to the patient’s retinal findings rather than apply one rule to every case.
Who is considered for photobiomodulation?
Photobiomodulation refers to the use of specific wavelengths of light delivered in a controlled clinical setting. In eye care, people who are typically considered for photobiomodulation are those with dry AMD whose exam suggests a potential role for this type of therapy and whose disease does not show active wet changes. Candidates are often evaluated by ophthalmologists or retina specialists who can compare visual acuity, symptoms, and imaging results before deciding whether treatment makes sense.
Specialists also tend to focus on expectations. Valeda is not generally presented as a cure for AMD, and candidacy discussions often include what the therapy may and may not do. A person may be viewed more favorably as a candidate when the retina is still structurally assessable, the diagnosis is stable, and the patient understands the need for follow-up. In many practices, willingness and ability to attend repeated sessions is a practical part of qualification because treatment is not a one-visit intervention.
Eye exam findings and candidacy
Eye exam findings that affect candidacy usually include what the doctor sees on optical coherence tomography, color fundus photography, and the dilated retinal exam. Common dry AMD features such as drusen, pigment changes, and other macular alterations help define the disease pattern. Just as important is what is not present: fluid, hemorrhage, or signs of choroidal neovascularization can shift the diagnosis toward wet AMD, which may make Valeda inappropriate or delay consideration until the eye is managed differently.
Other exam details can matter as well. Significant cataract, corneal opacity, poor fixation, or any problem that prevents a clear view of the retina may influence whether treatment can be performed effectively. Doctors may also weigh other retinal conditions, such as diabetic retinal disease or macular disorders unrelated to AMD, because overlapping pathology can make it harder to judge benefit or safety. Visual acuity measurements, contrast sensitivity, and the patient’s functional complaints may all contribute to the final recommendation.
When Valeda light therapy may not fit
Valeda light therapy may not be appropriate when the person has wet AMD, active retinal bleeding, fluid under or within the retina, or another eye condition that takes priority. It may also be a poor fit when the macula has advanced structural damage, extensive scarring, or disease features that suggest limited potential for functional improvement. In those cases, a specialist may decide that monitoring, low-vision support, nutritional counseling, or other retinal treatments are more relevant than photobiomodulation.
There are also practical reasons someone may not move forward. If a patient cannot tolerate the positioning required for treatment, cannot return for scheduled sessions, or has ocular media issues that interfere with delivery or monitoring, a clinic may decide the treatment is not suitable at that time. Some people are evaluated and told to defer treatment until additional testing is completed or until the diagnosis is clarified. That is why candidacy is best understood as a clinical judgment based on the whole picture, not as a simple yes-or-no checklist.
In the United States, qualification for Valeda light therapy generally depends on having confirmed dry AMD, retinal findings that align with how the treatment is used, and no active signs of wet disease that would point care in another direction. The most important factors are the retinal exam, imaging results, disease stage, and realistic treatment goals. For many patients, the question is less about age alone and more about whether the eye’s current condition makes photobiomodulation a reasonable option within a broader AMD care plan.